GlassScriptPhysician profile
Kenneth J Boomgaard
NPI 1427047034
$4,687.03
in general payments reported to CMS, 2019-2025
34 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $337 · 2021: $877 · 2022: $890 · 2023: $1,060 · 2024: $590 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.30 | 2021-2025 | Ubrelvy, Vraylar |
| Medtronic, INC. | $487.54 | 2021-2025 | Accurian, Inceptiv, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $453.37 | 2021-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $380.62 | 2021-2025 | Eterna, Proclaim |
| Teva Pharmaceuticals USA, INC. | $274.61 | 2019-2025 | Ajovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.07 | 2019-2024 | Relistor |
| Pfizer INC. | $206.19 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $178.31 | 2021-2025 | Xeomin |
| Amgen INC. | $162.35 | 2019-2022 | |
| Allergan, INC. | $146.62 | 2019-2020 | |
| Averitas Pharma INC. | $125.39 | 2023-2025 | Qutenza |
| Biohaven Pharmaceuticals, INC. | $111.05 | 2020-2021 | |
| Nevro Corp. | $110.73 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.92 | 2022 | |
| Grt US Holding, INC. | $85.02 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $61.62 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $60.12 | 2024-2025 | |
| Lilly USA, LLC | $55.46 | 2022-2023 | Emgality |
| Depuy Synthes Sales INC. | $50.67 | 2019-2025 | Monovisc, Orthovisc |
| Ibsa Pharma INC. | $44.26 | 2021-2023 | Tirosint, Licart |
| Supernus Pharmaceuticals, INC. | $42.76 | 2020 | |
| Azurity Pharmaceuticals, INC. | $40.67 | 2023 | Horizant |
| Tactile Systems Technology INC | $38.82 | 2020 | |
| Lundbeck LLC | $35.43 | 2023-2025 | Vyepti |
| Si-Bone, INC. | $33.54 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $26.07 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.99 | 2024 | Iovera |
| Relievant Medsystems, INC. | $21.28 | 2023 | Intracept |
| Novartis Pharmaceuticals Corporation | $20.10 | 2019 | |
| Bioventus LLC | $18.25 | 2019 | |
| Medtronic USA, INC. | $17.23 | 2019 | |
| Indivior INC. | $16.00 | 2024 | Sublocade |
| Piramal Critical Care | $15.17 | 2021 | |
| Eisai INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Boomgaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.